Prochymal: Expanded access program data

Data from 59 pediatric patients enrolled in an international expanded access program (Protocol 275) showed that 2 infusions of Prochymal per week for 4 weeks resulted in an overall response rate of 63% at day 28. When assessed by organ, Prochymal resulted in an overall response rate of 47% for skin, 23% for gastrointestinal and 39% for liver GvHD at day 28. Additionally, patients who responded to Prochymal at day 28 showed a significantly higher probability of survival to day 100 vs. patients who progressed (78% vs. 9%, p<0.05). Prochymal was well tolerated with no evidence of ectopic tissue formation and no serious adverse events reported. Data were presented at the Center for International Blood and Marrow Transplant Research and the American Society of Blood and Marrow Transplantation tandem meeting in Orlando. ...